Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis Drops SCD Gene Therapy Program with Intellia
BioSpace
Fri, 02/24/23 - 09:03 am
Tags:
Novartis, sickle cell disease, Intellia Therapeutics, CRISPR, gene editing
Novartis, Roche avoid $475M antitrust fine in French appeals court
Fierce Pharma
Mon, 02/20/23 - 12:57 pm
Tags:
Novartis, Roche, antitrust, Lucentis
Novartis loses $940M arbitration case against Mitsubishi Chemical over Gilenya royalties
Fierce Pharma
Mon, 02/20/23 - 12:42 pm
Tags:
Novartis, Mitsubishi Chemical, multiple sclerosis, MS, Supreme Court, legal, patents, Gilenya
Sandoz files biosimilar of Amgen osteoporosis drug in US
Pharmaphorum
Tue, 02/7/23 - 12:22 pm
Tags:
Sandoz, Novartis, biosimilars, osteoporosis, Prolia, Xgeva, FDA
Novartis CEO, as incoming PhRMA chair, outlines 3 priorities for pharma after IRA setback
Fierce Pharma
Wed, 02/1/23 - 10:22 pm
Tags:
Novartis, Vas Narasimhan, PhRMA, Inflation Reduction Act, PBMs, small molecule drugs
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
Yahoo/Benzinga
Wed, 02/1/23 - 10:39 am
Tags:
Novartis, earnings, Sandoz
Novartis' approved sickle cell disease drug fails to beat placebo in PhIII
Endpoints
Sun, 01/29/23 - 01:23 pm
Tags:
Novartis, sickle cell disease, Adakveo, clinical trials
Anthos doubles down on its novel blood thinner
EP Vantage
Fri, 01/27/23 - 10:34 am
Tags:
Anthos, Novartis, Factor XI inhibitor, bloodthinners, abelacimab
Could This Be Novartis' Next Blockbuster Medicine?
Motley Fool
Fri, 01/27/23 - 10:27 am
Tags:
Novartis, iptacopan, PNH
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
Endpoints
Thu, 01/26/23 - 05:05 pm
Tags:
Regeneron, Novartis, Eylea, drug delivery, patents, Lucentis
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
Fierce Pharma
Thu, 01/26/23 - 10:40 am
Tags:
Gilead Sciences, CAR-T, Yescarta, UK, NICE, Kite Pharma, Novartis, blood cancer
Sandoz signs deal for antifungal from Astellas in buff-up of anti-infectives portfolio
Endpoints
Wed, 01/25/23 - 10:44 am
Tags:
Sandoz, Novartis, Astellas, antifungals, Mycamine, generics
Novartis petitions Supreme Court in effort to 'vigorously defend' Gilenya patent
Endpoints
Tue, 01/24/23 - 06:18 pm
Tags:
Novartis, Supreme Court, Gilenya, patents, generics, multiple sclerosis, MS
Novartis CEO says Covid likely to become endemic, urges investment in pandemic preparedness
CNBC
Fri, 01/20/23 - 10:32 am
Tags:
Novartis, Pharma CEOs, Vas Narasimhan, COVID-19, pandemic, Public Health
A year of two halves for US approvals
EP Vantage
Thu, 01/19/23 - 09:38 am
Tags:
FDA, drug approvals, Mounjaro, Eli Lilly, Vabysmo, Roche, Opdualag, Bristol Myers Squibb, Carvykti, JNJ, Vtama, Roivant, Pluvicto, Novartis
AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out
Fierce Pharma
Wed, 01/18/23 - 10:53 pm
Tags:
AbbVie, Novartis, China, drug pricing, Pfizer, Paxlovid
EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma
BioPharma Dive
Tue, 01/17/23 - 10:26 am
Tags:
Novartis, gene therapy, Zolgensma, SMA, Europe
JPM23: After rock climbing in biotech, Novartis' CMO is back to support hopeful hike to US summit
Fierce Biotech
Thu, 01/12/23 - 10:36 am
Tags:
Novartis, JPMHC 2023, Dicerna Pharmaceuticals, Axcella Health
JPM Day 1: Highlights
BioSpace
Mon, 01/9/23 - 11:01 pm
Tags:
JPMHC 2023, Sarepta Therapeutics, Biomarin, Alnylam, JNJ, Arrowhead Pharmaceuticals, Novartis, Bristol Myers Squibb
JPM23: Is Novartis weighing respiratory, eye drug sell-offs after Sandoz? Not necessarily, CEO says
Fierce Pharma
Mon, 01/9/23 - 10:43 pm
Tags:
Novartis, JPMHC 2023, Sandoz, Respiratory, eye health

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.